Stem Cell Characterization and Analysis Tool Market Size Analysis: Growth Factors, Share by Regional Production, Revenue and Regional Trends with Key…

Global Stem Cell Characterization and Analysis Tool Market 2020 report consists of important factors such as the latest trends, performance drivers, key players, revenue, growth rate and volume sales, and consumer insights. The report Stem Cell Characterization and Analysis Tool Market gives detailed information on enterprises on a global and regional level through an all-inclusive analysis and insights into developments affecting businesses. It accommodates an entire overview of the market, including the market size, share, and the projection of this global market, within a specific interval of time. Then, it covers the major players functioning in Stem Cell Characterization and Analysis Tool market.

Get a Sample PDF of Report https://www.marketreportsworld.com/enquiry/request-sample/16070853

The Global Stem Cell Characterization and Analysis Tool market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Characterization and Analysis Tool market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

To Understand How COVID-19 Impact is Covered in this Report. Get Sample Copy of the report at-

https://www.marketreportsworld.com/enquiry/request-covid19/16070853

The research covers the current Stem Cell Characterization and Analysis Tool market size of the market and its growth rates based on 6-year records with company outline of Key players/manufacturers:

About Stem Cell Characterization and Analysis Tool Market:

Stem cell characterization is the study of tissue-specific differentiation. There are various type of stem cell such as embryonic stem cell, epithelial stem cell and others. Further, various techniques are used to characterized stem cells such as immunological techniques, used for depiction of different population of stem cells. These techniques are generally based on immunochemistry using staining technique or florescent microscopy. Besides, stem cells characterization and analysis tools are used against target chronic diseases.Market Analysis and Insights: Global Stem Cell Characterization and Analysis Tool MarketThe global Stem Cell Characterization and Analysis Tool market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stem Cell Characterization and Analysis Tool market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stem Cell Characterization and Analysis Tool market in terms of revenue.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cell Characterization and Analysis Tool market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cell Characterization and Analysis Tool market.Global Stem Cell Characterization and Analysis Tool Scope and Market SizeStem Cell Characterization and Analysis Tool market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stem Cell Characterization and Analysis Tool market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.Market segment by Type, the product can be split into Services Software Instruments Accessories Consumables Reagent and Assay KitsMarket segment by Application, split into Neurological Disorders Orthopedic Treatments Oncology Disorders Diabetes Other Therapeutic Applications Drug Development and Discovery Embryonic Stem Cells ResearchBased on regional and country-level analysis, the Stem Cell Characterization and Analysis Tool market has been segmented as follows: North America United States Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Latin America Mexico Brazil Middle East & Africa Turkey Saudi Arabia UAE Rest of Middle East & AfricaIn the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell Characterization and Analysis Tool market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this study Osiris Therapeutics, Inc. Caladrius Biosciences, Inc. U.S. Stem Cell, Inc. Astellas Pharma Inc. TEMCELL Technologies Inc. BioTime Inc. Cellular Engineering Technologies Inc. Cytori Therapeutics, Inc. BrainStorm Cell Therapeutics Inc.

This report focuses on the Stem Cell Characterization and Analysis Tool in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the Stem Cell Characterization and Analysis Tool Market Report 2020

Report further studies the market development status and future Stem Cell Characterization and Analysis Tool Market trend across the world. Also, it splits Stem Cell Characterization and Analysis Tool Market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Characterization and Analysis Tool in these regions, from 2015 to 2026, covering

This Stem Cell Characterization and Analysis Tool Market Research/Analysis Report Contains Answers to your following Questions

Enquire Before Purchasing This Report at

https://www.marketreportsworld.com/enquiry/pre-order-enquiry/16070853

Major Points from Table of Contents:

1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Stem Cell Characterization and Analysis Tool Market Size Growth Rate by Type: 2020 VS 2026 1.2.2 Services 1.2.3 Software 1.2.4 Instruments 1.2.5 Accessories 1.2.6 Consumables 1.2.7 Reagent and Assay Kits 1.3 Market by Application 1.3.1 Global Stem Cell Characterization and Analysis Tool Market Share by Application: 2020 VS 2026 1.3.2 Neurological Disorders 1.3.3 Orthopedic Treatments 1.3.4 Oncology Disorders 1.3.5 Diabetes 1.3.6 Other Therapeutic Applications 1.3.7 Drug Development and Discovery Embryonic Stem Cells Research 1.4 Study Objectives 1.5 Years Considered

2 Global Growth Trends 2.1 Global Stem Cell Characterization and Analysis Tool Market Perspective (2015-2026) 2.2 Global Stem Cell Characterization and Analysis Tool Growth Trends by Regions 2.2.1 Stem Cell Characterization and Analysis Tool Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Stem Cell Characterization and Analysis Tool Historic Market Share by Regions (2015-2020) 2.2.3 Stem Cell Characterization and Analysis Tool Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Market Restraints

3 Competition Landscape by Key Players 3.1 Global Top Stem Cell Characterization and Analysis Tool Players by Market Size 3.1.1 Global Top Stem Cell Characterization and Analysis Tool Players by Revenue (2015-2020) 3.1.2 Global Stem Cell Characterization and Analysis Tool Revenue Market Share by Players (2015-2020) 3.2 Global Stem Cell Characterization and Analysis Tool Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Stem Cell Characterization and Analysis Tool Revenue 3.4 Global Stem Cell Characterization and Analysis Tool Market Concentration Ratio 3.4.1 Global Stem Cell Characterization and Analysis Tool Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Stem Cell Characterization and Analysis Tool Revenue in 2019 3.5 Key Players Stem Cell Characterization and Analysis Tool Area Served 3.6 Key Players Stem Cell Characterization and Analysis Tool Product Solution and Service 3.7 Date of Enter into Stem Cell Characterization and Analysis Tool Market 3.8 Mergers & Acquisitions, Expansion Plans

4 Stem Cell Characterization and Analysis Tool Breakdown Data by Type (2015-2026) 4.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Type (2015-2020) 4.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Type (2021-2026)

5 Stem Cell Characterization and Analysis Tool Breakdown Data by Application (2015-2026) 5.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Application (2015-2020) 5.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Application (2021-2026)

6 North America 6.1 North America Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 6.2 North America Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 6.3 North America Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 6.4 North America Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 6.4.1 United States 6.4.2 Canada

7 Europe 7.1 Europe Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 7.2 Europe Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 7.3 Europe Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 7.4 Europe Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 7.4.6 Nordic 7.4.7 Rest of Europe

8 China 8.1 China Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 8.2 China Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 8.3 China Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 8.4 China Stem Cell Characterization and Analysis Tool Market Size by Region (2015-2020) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 Southeast Asia 8.4.5 India 8.4.6 Australia 8.4.7 Rest of Asia-Pacific

9 Japan 9.1 Japan Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 9.2 Japan Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 9.3 Japan Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 9.4 Japan Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 9.4.1 Mexico 9.4.2 Brazil

10 Southeast Asia 10.1 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2026) 10.2 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 10.3 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 10.4 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Country (2015-2020) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles 11.1 Osiris Therapeutics, Inc. 11.1.1 Osiris Therapeutics, Inc. Company Details 11.1.2 Osiris Therapeutics, Inc. Business Overview 11.1.3 Osiris Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.1.4 Osiris Therapeutics, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020)) 11.1.5 Osiris Therapeutics, Inc. Recent Development 11.2 Caladrius Biosciences, Inc. 11.2.1 Caladrius Biosciences, Inc. Company Details 11.2.2 Caladrius Biosciences, Inc. Business Overview 11.2.3 Caladrius Biosciences, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.2.4 Caladrius Biosciences, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.2.5 Caladrius Biosciences, Inc. Recent Development 11.3 U.S. Stem Cell, Inc. 11.3.1 U.S. Stem Cell, Inc. Company Details 11.3.2 U.S. Stem Cell, Inc. Business Overview 11.3.3 U.S. Stem Cell, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.3.4 U.S. Stem Cell, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.3.5 U.S. Stem Cell, Inc. Recent Development 11.4 Astellas Pharma Inc. 11.4.1 Astellas Pharma Inc. Company Details 11.4.2 Astellas Pharma Inc. Business Overview 11.4.3 Astellas Pharma Inc. Stem Cell Characterization and Analysis Tool Introduction 11.4.4 Astellas Pharma Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.4.5 Astellas Pharma Inc. Recent Development 11.5 TEMCELL Technologies Inc. 11.5.1 TEMCELL Technologies Inc. Company Details 11.5.2 TEMCELL Technologies Inc. Business Overview 11.5.3 TEMCELL Technologies Inc. Stem Cell Characterization and Analysis Tool Introduction 11.5.4 TEMCELL Technologies Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.5.5 TEMCELL Technologies Inc. Recent Development 11.6 BioTime Inc. 11.6.1 BioTime Inc. Company Details 11.6.2 BioTime Inc. Business Overview 11.6.3 BioTime Inc. Stem Cell Characterization and Analysis Tool Introduction 11.6.4 BioTime Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.6.5 BioTime Inc. Recent Development 11.7 Cellular Engineering Technologies Inc. 11.7.1 Cellular Engineering Technologies Inc. Company Details 11.7.2 Cellular Engineering Technologies Inc. Business Overview 11.7.3 Cellular Engineering Technologies Inc. Stem Cell Characterization and Analysis Tool Introduction 11.7.4 Cellular Engineering Technologies Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.7.5 Cellular Engineering Technologies Inc. Recent Development 11.8 Cytori Therapeutics, Inc. 11.8.1 Cytori Therapeutics, Inc. Company Details 11.8.2 Cytori Therapeutics, Inc. Business Overview 11.8.3 Cytori Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Introduction 11.8.4 Cytori Therapeutics, Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.8.5 Cytori Therapeutics, Inc. Recent Development 11.9 BrainStorm Cell Therapeutics Inc. 11.9.1 BrainStorm Cell Therapeutics Inc. Company Details 11.9.2 BrainStorm Cell Therapeutics Inc. Business Overview 11.9.3 BrainStorm Cell Therapeutics Inc. Stem Cell Characterization and Analysis Tool Introduction 11.9.4 BrainStorm Cell Therapeutics Inc. Revenue in Stem Cell Characterization and Analysis Tool Business (2015-2020) 11.9.5 BrainStorm Cell Therapeutics Inc. Recent Development

12 Analysts Viewpoints/Conclusions

13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

Purchase this report (Price 3900 USD for a single user license)

https://www.marketreportsworld.com/purchase/16070853

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email:[emailprotected]

Phone:US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Lemon Essential Oil Battery Market Size 2020 Business Strategies, Opportunities, Future Trends, Top Key Players, Market Share, and Forecast 2023

Garden Tillers Market Size, Share 2020 Global Industry Trends, Sales Revenue, Industry Growth, Development Status, Top Leaders, Future Plans and Opportunity Assessment 2026

Global Microgrid Market Size, Share 2020|Global Industry by Growth Insight, Key Development, Trends, Business Anaslysis, and Forecast by Market Reports World

Epoxy Polyester Powder Coatings Market Size, Share 2020 Explosive Factors of Revenue by Key Vendors, Demand, Development Strategy, Future Trends and Industry Growth Research Report

Global Isotopes Market 2020 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications by Market Research Report to 2025

Pizza Ovens for Commercial Use Market Size, Share Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast 2026

Telescope and Hand-held Later Rangefinder Market 2020 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2026

Music Production Software Market Size, Share 2020 Global Industry Demand, Recent Trends, Estimation by 2023 with Top Players MarketReportsWorld.com

Swine Feed Premix Market 2020 Global Industry Share, Size, Future Demand, Global Research, Top Leading Players, Emerging Trends, Region by Forecast to 2023

Laboratory Stability Test Chambers Market Size, Share 2020 Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2026

Originally posted here:
Stem Cell Characterization and Analysis Tool Market Size Analysis: Growth Factors, Share by Regional Production, Revenue and Regional Trends with Key...

Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update – Galveston County Daily News

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov 12, 2020--

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the third quarter ended September 30, 2020. The company also highlighted recent progress and upcoming milestones for its pipeline programs.

We are very pleased with our strong pipeline progress during the quarter amid such challenging times, said Frank Lee, President and Chief Executive Officer of Forma. We look forward to presenting new data from our ongoing Phase 1 trial of FT-4202 in sickle cell disease at the ASH meeting in December, as well as beginning enrollment of patients for our Phase 1 trial of FT-7051 in men living with metastatic castration-resistant prostate cancer. The recent positive top-line results from the olutasidenib registrational Phase 2 clinical trial in relapsed/refractory acute myeloid leukemia with an IDH1 mutation further underscores our commitment to developing transformative therapies for patients.

Key Business and Clinical Highlights

PKR Program in Sickle Cell Disease (SCD):

CPB/p300 Program in Prostate Cancer:

IDH1 Program in AML and Glioma:

Corporate:

Upcoming Milestones

Upcoming Investor Events

Financial Results

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit http://www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the companys beliefs and expectations regarding its: business plans and objectives; future plans for FT-4202 and FT-7051, including expectations regarding timing and success of the current ongoing clinical trials, therapeutic potential and clinical benefits thereof, and upcoming milestones for the companys other product candidates; growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress; presentation of additional data at upcoming scientific conferences, and other preclinical data in 2020; the potential commercial and collaboration opportunities, including potential future collaborators and parties, as well as value and market, for our product candidates; uses of capital, expenses and other 2020 financial results or in the future, and the potential impact of COVID-19 on patient retention, strategy, future operations, clinical trials or IND submissions. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on the companys business, operations, strategy, goals and anticipated milestones; the therapeutic potential of FT-4202, and the timing associated with the initiation or continuation of any of FT-4202 trials; the initiation of our phase I clinical trial of FT-7051; Formas ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Formas ability to fund operations; Formas ability to identify satisfactory collaboration opportunities, as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the final prospectus dated June 22, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Formas filings and reports with the SEC. Forma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Formas views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Forma explicitly disclaims any obligation to update any forward-looking statements.

2020

2019

2020

2019

$ -

$ 3,377

$ -

$ 93,113

24,780

27,558

68,501

84,273

7,460

7,025

22,841

17,631

-

545

63

5,620

32,240

35,128

91,405

107,524

(32,240)

(31,751)

(91,405)

(14,411)

818

766

23,050

3,057

(31,422)

(30,985)

(68,355)

(11,354)

(3,806)

-

(26,529)

(1,217)

$ (27,616)

$ (30,985)

$ (41,826)

$ (10,137)

-

(607)

(3,736)

(2,395)

-

-

-

(11,347)

-

(60)

-

(60)

$ (27,616)

$ (45,562)

(8)

-

$ (27,624)

$ (45,562)

$ (31,652)

$ (23,939)

(198)

(515)

$ (31,850)

$ (24,454)

$ (0.67)

$ (2.74)

$ (0.67)

$ (2.74)

$ (12.42)

$ (9.40)

$ (12.50)

$ (9.60)

41,088,261

16,616,143

41,088,924

16,616,143

2,547,924

Read the original here:
Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Galveston County Daily News

Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 – BCFocus

Data Bridge Market Research has recently published the Global research Report TitledAdipose Tissue-Derived Stem Cells (ADSCS) Market.

TheAdipose Tissue-Derived Stem Cells (ADSCS) Marketreport gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market. This market research report also provides thorough information about target markets or customers. Global Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a sure-fire solution that businesses can adopt to thrive in this swiftly changing marketplace. For outstanding business growth, companies must take upmarket research report service which has become enough vital in todays market place.

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

This report examines all the key factors influencing the growth of Adipose Tissue-Derived Stem Cells (ADSCS) market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of Adipose Tissue-Derived Stem Cells (ADSCS) market unlocks a plethora of untapped opportunities in regional and domestic marketplaces. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

Get Free Sample Copy of the Report to Understand the Structure of the Complete Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

The Global Adipose Tissue-Derived Stem Cells (ADSCS) Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Adipose Tissue-Derived Stem Cells (ADSCS) market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Adipose Tissue-Derived Stem Cells (ADSCS) Market in each region. Various methodological tools are used to analyze the growth of the worldwide Adipose Tissue-Derived Stem Cells (ADSCS) market.

Prominent Key Players Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

A complete value chain of the global Adipose Tissue-Derived Stem Cells (ADSCS) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Adipose Tissue-Derived Stem Cells (ADSCS) Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Adipose Tissue-Derived Stem Cells (ADSCS) market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Adipose Tissue-Derived Stem Cells (ADSCS) market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

How Does This Market Insights Help?

Key Pointers Covered in the Adipose Tissue-Derived Stem Cells (ADSCS) Market Industry Trends and Forecast

Reasons to Purchase this Report

Request Free Sample PDF (including COVID19 Impact Analysis) of Adipose Tissue-Derived Stem Cells (ADSCS) MarketReport@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Market Dynamics:The Adipose Tissue-Derived Stem Cells (ADSCS) report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report givesinformation such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Original post:
Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - BCFocus

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results – PRNewswire

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

"This quarter, our Company reached a significant milestone by initiating our first Marker-sponsored studya Phase 2 trial of zelenoleucel or MT-401, our lead MultiTAA-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia," said Peter L. Hoang, President & CEO of Marker Therapeutics. "We have enrolled the first patient in the safety lead-in portion of the trial, and are in the process of scheduling the donor in order to manufacture the product."

Continued Mr. Hoang: "During this unprecedented time, we have made significant progress by enrolling additional clinical sites for our AML trial, advancing our manufacturing process, reducing production time by 50% and improving the potency of our MT-401 product, and entering the final phase of the construction of our new in-house cGMP manufacturing facility. I am extremely proud of the dedication and resolve that our team has shown during these challenging months. I want to acknowledge their hard work across the organization that went into achieving these milestones."

PROGRAM UPDATES

MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML

Phase 2 AML Trial The Company initiated the safety lead-in portion of its Phase 2 study of zelenoleucel (MT-401) in patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings. The Company anticipates treating the first patient by Q1 2021. The safety lead-in is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and the remaining three to be treated with study drug manufactured with a new reagent from an alternate supplier.

Marker has activated four clinical sites and is in the start-up phase with additional clinical sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates activating a total of approximately 20 sites.

The study remains on partial clinical hold pending the review of final data and subsequent acceptance of certificates of analysis for the new reagent by the U.S. FDA. The Company received the remaining reagent from the alternate supplier in Q3 2020 and is currently conducting the comparability analyses between the previous and new reagents, as required by FDA. Marker intends to submit all required data to FDA by Q1 2021 to enable removal of the partial clinical hold.

Over the past year, the Company has continued to streamline and simplify the MT-401 manufacturing process. The technical improvements include a 50% reduction in manufacturing time, a 95% reduction in the number of required operator interventions, and significant improvement in the consistency and reproducibility of the manufacturing process, while yielding a significant increase in the number of T cells available for patient administration. The Company expects the new process to yield a measurably improved product, with superior T cell phenotype and antigen specificity as compared to the original process. The new process improvements have been updated in the CMC section of the IND and will be used for all patients in the Marker AML clinical trial.

BUSINESS UPDATES

THIRD QUARTER 2020 FINANCIAL RESULTS

Cash Position and Guidance:At September 30, 2020, Marker had cash and cash equivalents of $27.0 million. The Company raised $2.2 million through the previously executed $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $27.8 million available to Marker from Aspire Capital along with current cash available, funds operations into Q1 2022.

R&D Expenses:Research and development expenses were$4.8 million for the quarter endedSeptember 30, 2020, compared to$3.1 million for the quarter ended September 30, 2019.

G&A Expenses:General and administrative expenses were$2.6 million for the quarter endedSeptember 30, 2020, compared to $2.5 million for the quarter ended September 30, 2019.

Net Loss:Marker reported a net loss of$7.4 millionfor the quarter endedSeptember 30, 2020, compared to a net loss of$5.5 million for the quarter ended September 30, 2019.

Conference Call and Webcast

The Company will host a webcast and conference call to discuss its third quarter 2020 financial results and provide a corporate update today at 5:00 PM EST.

The webcast will be accessible in theInvestorssection of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics Third Quarter 2020 Earnings Call."

The archived webcast will be available for replay on the Marker website following the event.

About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; the timing, conduct and success of our clinical trials, as well as clinical trials conducted by our collaborators; our manufacturing processes and our ability to use our in-house manufacturing facility to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.

Condensed Consolidated Balance Sheets

September 30,

December 31,

2020

2019

(Unaudited)

(Audited)

ASSETS

Current assets:

Cash and cash equivalents

$ 26,956,737

$ 43,903,949

Prepaid expenses and deposits

2,367,145

1,526,442

Interest receivable

135

56,189

Other receivable

1,000,000

-

Total current assets

30,324,017

45,486,580

Non-current assets:

Property, plant and equipment, net

2,629,628

417,528

Construction in progress

4,557,581

-

Right-of-use assets, net

11,059,962

455,174

Total non-current assets

18,247,171

872,702

Total assets

$ 48,571,188

$ 46,359,282

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$ 5,746,149

$ 1,757,680

Lease liability

278,333

204,132

Warrant liability

-

31,000

Total current liabilities

6,024,482

1,992,812

Non-current liabilities:

Lease liability, net of current portion

11,948,781

280,247

Total non-current liabilities

11,948,781

280,247

Total liabilities

17,973,263

2,273,059

Commitments and contingencies

-

-

Stockholders' equity:

Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

-

-

Common stock, $0.001 par value, 150 million shares authorized, 48.0 million and 45.7 million shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

48,025

45,728

Additional paid-in capital

378,282,157

371,573,909

Go here to see the original:
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - PRNewswire

CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health…

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders and diseases with an initial focus on neuropathic pain and epilepsy, today announced it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). As part of theNIH Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, the funding of $670,000 over two years will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain. Orion P. Keifer, Jr. M.D., Ph.D., Vice President, Discovery and Translation at CODA, will serve as the program's principal investigator.

"We are unwavering in our commitment to developing novel chemogenetic therapies for the treatment of neurological disorders and diseases like neuropathic pain for which current treatment options have significant limitations," said Michael Narachi, President and Chief Executive Officer, CODA. "We are honored to receive this grant from NINDS, as this funding will help advance our chemogenetic platform toward human clinical trials where we hope to demonstrate transformative results for patients."

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach for neuropathic pain by deploying a chemogenetic strategy for treating neuropathic pain sensations at their origin. The Company's innovative treatment aims to modulate specific neuronal circuits where pain arises via adeno-associated virus-mediated delivery of an engineered inhibitory receptor. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable pain relief while potentially avoiding off-target/adverse effects of currently available treatments.

The NINDS SBIR/Small Business Technology Transfer (STTR) program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public health benefit.

In addition, CODA was recently selected to collaborate with NIH's National Center for Advancing Translational Science (NCATS), also as part of the NIH HEAL initiative. CODA will partner with the Stem Cell Translation Laboratory led by Ilyas Singec, M.D., Ph.D., in the NCATS Division of Preclinical Innovation (DPI) in developing induced pluripotent stem cell (iPSC)-derived human Ab sensory neurons for the identification and characterization of novel neuropathic pain therapies. The joint NCATS/CODA collaboration will leverage expertise and technologies available at Dr. Singec's lab to jointly develop protocols for generating iPSC-derived A primary sensory neurons, which CODA will then use for the identification and evaluation of inhibitory chemogenetic receptors for the treatment of neuropathic pain. G. Steven Dodson, Ph.D., Vice President of Pharmacology and Early Development at CODA will serve as lead collaborator.

"Ab neurons are a key cell type for the evaluation of our receptor-ligand combinations and their development should advance the translational understanding of how our approach may impact pain states in patients. Through this partnership, CODA will collaborate with and gain access to the scientific capabilities, expertise, state-of-the-art technologies, and resources of the NCATS DPI to develop iPSC-derived human Ab sensory neurons, which will help us progress our neuropathic pain therapies toward the clinic," added Mr. Narachi.

About Neuropathic Pain According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.

About the CODA Platform CODA's chemogenetic platform aims to reverse the aberrant neuronal activity underlying many neurological disorders. With chemogenetics, dysfunctional neurons are modified using optimized adeno-associated virus (AAV) vectors delivered directly to them by standard-of-care neurosurgical procedures. The AAV vectors encode ligand-gated ion channels (chemogenetic receptors) that are highly responsive to specific proprietary small molecule therapeutics but are otherwise inactive. The activity of these receptors, and thus the aberrant activity of the modified neurons, is controlled in a selective and tunable manner through administration of the small molecule to generate therapeutic benefit with minimal side effects.

About CODA Biotherapeutics CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders and diseases. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit http://www.codabiotherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

SOURCE CODA Biotherapeutics, Inc.

View original post here:
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...